Night Terrors Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Night Terrors Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Night Terrors; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Night Terrors receives an overall strategic score of 71/100. The opportunity combines an unmet-need score of 85/100, competition score of 49/100 and market-attractiveness score of 70/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

A disorder characterized by incomplete arousals from sleep associated with behavior suggesting extreme fright. This condition primarily affects children and young adults and the individual generally has no recall of the event. Episodes tend to occur during stage III or IV. SOMNAMBULISM is frequently associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p391)

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Night Terrors, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID ad2532a04c0340c8bbc7ba1a5caf1e70 and MeSH identifier D020184. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Global report on neglected tropical diseases 2025 2.1 Progress against road map indicators 2021–2030

• Under the independence scenario, the prevalence rate declined from 0.355 in 1990 to 0.137 in 2021, resulting in a corresponding drop in the number of affected individuals from nearly 1.9 billion to just over 1.0 billion. The average prevalence rate was 0.238, with 1.51 billion people affected per year. • The maximal scenario yielded the lowest average prevalence rate of 0.137, with 866 million individuals affected annually; the prevalence rate and the number of people affected decreased from 0.217 and 1.158 billion in 1990 to 0.075 and 595 million in 2021. Whichever scenario is used, the trend is consistent and underscores substantial progress in reducing disease burden over the past three decades, even amid population growth. Taken together, the scenario-based estimates for 2021 and the long-term trend data reinforce the importance of interpreting NTD prevalence as a range, rather than as a single fixed figure. This allows for better reflection of real-world complexities such as co-endemicity, programmatic scale-up and socioeconomic disparities in disease exposure. NTD prevalence: projections and limitations Based on historical trends from 1990 to 2021 and projections using the independence coinfection scenario, the number of individuals affected by at least one NTD is expected to continue declining until 2030 (Fig. 2.13). In 2022, the estimated number of affected individuals was approximately 1.06 billion (95% confidence interval [CI]: 1.04–1.08 billion). By 2030, this number is projected to decrease to 860 million (95% CI: 693–1.03 billion), representing a reduction of

Review the underlying epidemiology source

Evidence signal 2: Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019 Global, regional, and nationalburden and attributable riskfactors of neurologicaldisorders: The Global Burden ofDisease study 1990–2019

In 2019, the incidence and prevalence of idiopathic epilepsy were 2,898.22 (2.098.72, 3.823.38) in thousands and 25,111.11 (19.033.57, 31.433.01) in thousands, respectively, which resulted in 13,077.62 (9.986.73, 16.734.09) thousands DALYs and 114.01(100.18, 129.93) thousands deaths. From 1990 to 2019, both numbers and age-standardized rates of incidence and prevalence increased, despite this trend, age-standardized rates of DALYs and deaths decreased (Table 1). The age-standardized DALY rate showed a strong negative correlation with the [SDIr = −0.68, p < 0.001 (Supplementary Table S3)]. In terms of age, idiopathic epilepsy mainly caused disease burden for the 5–30 years old group (Figure 4). Neural tube defects Neural tube defects caused 7,743.43 (95%UI 5,726.20, 11,022.80) thousands DALYs in 2019, which showed a decreasing trend of 47.1% (95%UI 32.40, 58.29) from 1990 to 2019. Crude numbers and age-standardized rates of incidence and deaths also decreased, but the prevalence increased. The burden on neural tube defects showed distinct regional distribution (Table 1 and Figure 1). It ranked the 15th in Western Europe, but ranked the 5th in Western sub-Saharan Africa (Figure 3). Age-standardized DALY rate showed a strong negative correlation with the SDI (r = −0.83, p < 0.001) (Supplementary Table S3). In terms of age, the disease burden of neural tube defects mainly impacted the early neonatal, post neonatal and 1–4 years old groups (Figure 4). Brain and central nervous system cancer

Review the underlying epidemiology source

Evidence signal 3: Epidemiological Features of Neurological Disorders in North Africa and the Middle East from 1990 to 2019: Results from the Global Burden of Disease Study 2019

In the NAME region, the incidence rate of neurological disorders increased by 0.84% (10006.37-10090.79), the prevalence rate increased by 1.36% (33711.72-34170.57), the mortality rate decreased by 2.75% (34.11-33.17), and the DALY rate decreased by 3.92% (1438.48-1382.14) between 1990 and 2019. In terms of ASR, the incidence rate of neurological disorders increased from 1990 to 2019 in the countries of the NAME region except for Algeria, Bahrain, Kuwait, Oman, Palestine, Qatar, Saudi Arabia, Sudan, and the United Arab Emirates. The highest incidence rates in 1990 pertained to the Islamic Republic of Iran 10802.77 (95% UI, 9740.21–11910) and Egypt 10148.8 (95% UI, 9060.23–11273.99), and the countries of Turkey 9507.57 (95% UI, 8483.29–10571.1) and Saudi Arabia 9656.09 (95% UI, 8605.59–10722.53) had the lowest incidence rate of neurological disorders, respectively. But in 2019, the Islamic Republic of Iran 11293.27 (95% UI, 10132.62– 12499.59) and Egypt 10257.33 (95% UI, 9189.37– 11341.16) continued to have the highest incidence rates of neurological disorders, while the lowest rate was found in Saudi Arabia 9582.12 (95% UI, 8516.51–10684.85) and Turkey 9588.75 (95% UI, 8564.72-10698.3).

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Night Terrors, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Night Terrors should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: GABRA1

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient (PubMed:23909897, PubMed:29950725, PubMed:30602789). Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation (PubMed:23909897, PubMed:25489750). GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity). GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity).

The proposed mechanism anchor for this landscape is GABRA1. Target selection does not imply that every Night Terrors patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 7 matched registered studies overall. The most recent records sampled for this report are:

• NCT07754838 — Acoustic Stimulation to Study and Modulate Sleepwalking and Related Arousal Disorders (DoA-CLAS); status: Not yet recruiting; phase: Not Applicable; sponsor(s): University of Applied Sciences and Arts of Southern Switzerland, University of Wisconsin-Madison, Swiss National Science Foundation; enrollment: 50.
• NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias; status: Recruiting; phase: Not Applicable; sponsor(s): University of Manitoba; enrollment: 20.
• NCT06612749 — Assessing the Impact of Integrative Medicine on Anxiety and Wellbeing of Healthcare Providers Exposed to Terror or War; status: Recruiting; phase: Not Applicable; sponsor(s): The Lady Davis Carmel Medical Center; enrollment: 600.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Night Terrors program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Night Terrors. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Night Terrors.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Night Terrors, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that GABRA1 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Night Terrors merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where GABRA1 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Night Terrors offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.